r With the development of the metabolic syndrome, both post-capillary and collecting venular dilator reactivity within the skeletal muscle of obese Zucker rats (OZR) is impaired.
Introduction
It is well established that the growing incidence and prevalence of the metabolic syndrome present a consistent threat to aggregate public health cardiovascular outcomes across many societies and developed economies (Vassalo et al. 2016; Mameli et al. 2017; Tune et al. 2017 ). This syndrome is broadly defined as the combined presentation of obesity, impaired glycaemic control, atherogenic dyslipidaemia and hypertension, with the additional contributing conditions of pro-oxidant, pro-thrombotic and pro-inflammatory phenotypes (Vassalo et al. 2016; American Heart Association, 2017) . While this condition is present in a growing number of afflicted persons worldwide, its influence on morbidity and mortality (Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration, 2014), as well as the economic costs that must be borne by society (Shamsedden et al. 2011; Trasande & Elbel, 2012) , mandate detailed investigation into this multi-pathology state.
While enormous investment has been made in understanding the impact of the metabolic syndrome on arterial/arteriolar and capillary function (Goodwill & Frisbee, 2012; Lemaster et al. 2017; Tune et al. 2017) , dedicated study of venular function has been limited and has largely focused on leukocyte-endothelial cell interactions as well as inflammatory and pro-thrombotic processes (Iba et al. 2012; Scallan et al. 2015; Estato et al. 2017) . Although these are important aspects of altered venular function, our understanding of venous tone regulation and its potential contribution to integrated microvascular function through the transition from health to disease is far from complete. Population health studies, using the retinal microcirculation as a 'window' into altered venular function, suggest that the control of venular diameter and venular network structure can be significantly altered with metabolic disease (Wong et al. 2004; Lammert et al. 2012; Zhao et al. 2012) . However, there has been a limited attempt at investigating these relationships in relevant animal models.
The obese Zucker rat (OZR; fa/fa) represents a translationally relevant model to study the metabolic syndrome, as cardiovascular disease in this model tracks well with cardiovascular (dys)function in afflicted humans. OZR develop the metabolic syndrome due to chronic hyperphagia based in leptin resistance, and rapidly develop all of the systemic phenotypes listed above to comparable levels of severity to that commonly identified in human subjects. Also similar to the health outcomes in humans, OZR exhibiting the metabolic syndrome suffer from a progressive vasculopathy that ultimately develops into overt peripheral vascular disease (Frisbee & Delp, 2006) , albeit one without the development of significant atherosclerotic lesions. While there has been extensive interrogation of the impact of metabolic syndrome on the arterial side of the microcirculation in OZR and in comparable models (Tune et al. 2017) , there has been less effort devoted to understanding the potential for altered venular function under these conditions and the potential impact on integrated microvascular function.
The purpose of the present study was to begin to understand how the function of in situ post-capillary and collecting venules from obese Zucker rats manifesting the full metabolic syndrome can be impacted as a result of the multi-pathology state. To assess this, we used an array of physiological and pharmacological challenges to understand how function is altered at these two levels within the venular networks. The present study tested the hypothesis that post-capillary and collecting venular function in the in situ skeletal muscle of OZR is altered in a manner that can increase venular blood flow resistance and negatively impact function within the capillary networks.
Methods

Ethical approval
All procedures in the present study had received prior review and approval by the Institutional Animal Care and Use Committee. All animal use procedures, including anaesthesia and killing, conform to standards established by the UK/European Union legislation (set out in in ASPA Schedule 1 in the UK and in Annex IV in the European Directive 2010/63/EU), the Canadian Council for Animal Care and the United States Department of Agriculture. All details of animal use are provided in the subsequent paragraphs.
Animals
Male lean Zucker rats (LZR; Harlan/Envigo) and obese Zucker rats (OZR; Harlan/Envigo) were acquired at 6-7 weeks of age, and after 1 week of acclimation, were aged to ß17 weeks of age. All animals were fed standard chow and tap water ad libitum for all experiments. On the experiment day, after an 8 h fast, rats were anaesthetized with injections of sodium pentobarbital (50 mg kg artery and an external jugular vein were cannulated for determination of arterial pressure and for intravenous infusion of additional substances as necessary (e.g. anaesthesia, heparin, etc.). Any animal in which mean arterial pressure was found to be below 85 mmHg (< 5% in both LZR and OZR), or where it had decreased by more than 15% from that following equilibration (without any pharmacological intervention; ß5% in LZR, ß10% in OZR) was not used in the present study. Blood samples were drawn from the venous cannula for determination of glucose and insulin concentrations (Millipore, Billerica, MA, USA), cholesterol/triglyceride levels (Wako Diagnostics, Richmond, VA, USA) and nitrotyrosine (Oxis International, Foster City, CA, USA). Blood gases were determined using a Corning RapidLab 248 Blood Gas Analyzer (Siemens Medical Solutions, Malvern, PA, USA). Unless otherwise noted, all drugs and chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA). Adequate depth of anaesthesia was confirmed at ß15 min intervals by monitoring ventilation patterns and noting an absence of whisker movement, startle and toe-pinch withdrawal reflexes. Additional anaesthetic was introduced in 10 mg kg −1 increments, as needed, through the jugular vein cannula. After all experiments, the anaesthetized rat was killed with an intravenous overdose of sodium pentobarbital (> 200 mg kg −1 ) followed by a bilateral pneumothoracotomy and physical removal of the heart. Due to the lasting effects of some of the pharmacological interventions and the inherent difficulties in reversing them, not all observations could be gathered from every animal. As a result, in specific experiment groups, the actual number of animals used can exceed the number of specific observations. This was done in order to preserve quality and experimental rigor. For clarity, total animal numbers used for the present study and their distribution across the experiment groups are summarized in Table 1 .
Preparation of in situ cremaster muscle
In each rat, the left cremaster muscle was prepared for television microscopy (Butcher et al. 2013) . After completion of the preparation, the cremaster muscle was superfused with physiological salt solution (PSS), equilibrated with a gas mixture containing 5% CO 2 and 95% N 2 , and maintained at 35°C as it flowed over the muscle. The ionic composition of the PSS was as follows (mM): NaCl 119.0, KCl 4.7, CaCl 2 1.6, NaH 2 PO 4 1.18, MgSO 4 1.17, and NaHCO 3 24.0. Venular diameter was determined with an on-screen video micrometer. After an initial post-surgical equilibration period of 30 min, venules of two sizes, ß75 μm diameter ('collecting') and ß25 μm diameter ('post-capillary'), were selected for investigation in a clearly visible region of the muscle. Venules selected for study had walls that were clearly visible, a brisk flow velocity and active tone, as indicated by the occurrence of significant dilatation in response to topical application of 10 −5 M adenosine. All venules studied were located in a region of the muscle that was away from any incision. In all experiments, at the conclusion of all procedures, 10 −3 M adenosine and 10 −3 M sodium nitroprusside were added to the superfusate to determine maximal diameter of the monitored venules.
Experiment group 1
These experiments were designed to determine fundamental cremaster muscle venular responses to pharmacological stimuli between LZR and OZR. Following an equilibration period, the responses of selected venules within the cremaster muscle of LZR and OZR were assessed in response to increasing concentrations of acetylcholine (10 −10 -10 −6 M), phenylephrine (α 1 -adrenoreceptor agonist; 10 −10 -10 −6 M), clonidine (α 2 -adrenoreceptor agonist, 10 −10 -10 −6 M), angiotensin II (vasoconstrictor peptide, 10 −10 -10 −6 M), endothelin (vasoconstrictor peptide, 10 −10 -10 −6 M) or acetylcholine (endothelium-dependent dilator, 10 −10 -10
Experiment group 2
These experiments determined basic signalling mechanisms that can contribute to the alterations in dilator reactivity to acetylcholine and the constrictor reactivity to phenylephrine determined between LZR and OZR in group 1. For these experiments, following the determination of baseline responses to acetylcholine and phenylephrine (as above), the cremaster muscle was treated with N ω -nitro-L-arginine methyl ester hydrochloride (L-NAME; nitric oxide synthase inhibitor; 10 −4 M), indomethacin (cyclooxygenase inhibitor; 10 −5 M), 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl −5 M). As in our previous studies (Butcher et al. 2013; Frisbee et al. 2014) , to exert maximum effectiveness, each inhibitor was applied for at least 45 min prior to evaluation of venular reactivity.
In a subset of animals from experiment groups 1 and 2, the cremaster muscle of LZR (n = 10) and OZR (n = 10) was treated with prazosin (α 1 -adrenoreceptor blocker, 10 −5 M), yohimbine (α 2 -adrenoreceptor blocker, 10 −5 M), or both and constrictor responses to noradrenaline (10 −10 -10 −6 M) were determined to assess any differences in receptor contribution between the strains.
Experiment group 3
These experiments determined basic signalling mechanisms that contribute to acetylcholine-induced dilatation or phenylephrine-induced constriction of cremaster muscle venules of LZR and OZR following pre-treatment with 10 −4 M TEMPOL. Following incubation with the antioxidant, venular responses to increasing concentrations of acetylcholine and phenylephrine were assessed under the new 'control' conditions, and following treatment of the muscle with L-NAME, indomethacin or SQ-29548, as described above.
Experiment group 4
These experiments determined the responses of in situ cremaster muscle venules of LZR and OZR in response to increased metabolic demand. Contraction of the cremaster muscle was evoked by 3 min of electrical field stimulation at 0.5, 1 or 3 Hz (400 ms duration, 60 Hz within train, 7 V; Grass SD 48, Astro-Med/Grass Technologies, West Warwick, RI, USA). At the conclusion of the muscle contraction period, venular diameter and centre-line erythrocyte velocity (optical Doppler velocimeter, Texas A&M University, College Station, TX, USA) were determined and used for the calculation of hyperaemic responses (see below).
Experiment group 5
These experiments determined the degree of leukocyte adhesion and rolling on the post-capillary venular endothelium between LZR and OZR. In a separate cohort of LZR and OZR, the in situ extensor digitorum longus muscle was prepared as described previously (Tyml & Budreau, 1991; Frisbee et al. 2014) . Following preparation of the muscle for imaging, 10 random high magnification fields of view (Plan-Neo 20×/0.5 and 40×/0.75; Zeiss, Thornwood, NY, USA) were recorded using a high-speed cooled digital imaging system (Axiocam HSm; Zeiss) for later analyses. Animals received a bolus injection of rhodamine 6G (0.3 mg kg −1 ; Sigma-Aldrich) to permit visualization of leukocytes. Rhodamine 6G-labelled vascular cells were visualized by epi-illumination at 510-560 nm, using a 590 nm emission filter. The number of rolling and adherent leukocytes in venules was expressed as cells mm −2 of endothelial surface, calculated from the diameter and length of the venular segment. Leukocytes were considered adherent if they remained stationary for a 30 s observation period. Leukocytes were considered rolling if their velocity was less than 250 μm s −1 (Zeintl et al. 1989) .
Histological determination of microvessel density
From LZR and OZR that were selected from each of the above groups, the gastrocnemius muscle from the left leg was removed, rinsed in PSS and fixed in 0.25% formalin. Muscles were embedded in paraffin and cut into 5 μm cross sections. Sections were incubated with Griffonia simplicifolia I lectin (GS-1) and dipeptidylpeptidase IV (DPEP IV), for subsequent determination of microvessel density. GS-1 is a general stain that labels all microvessels < 20 μm in diameter (Greene et al. 1990 ) and DPEP IV preferentially stains venular ends of capillaries (Mrázková et al. 1986 ). Labelled microvessel density was determined using fluorescent (for GS-1) or light microscopy (for DPEP IV) as described previously .
Determination of vascular metabolites of arachidonic acid
Vascular production of 6-keto-prostaglandin F 1 α (6-keto-PGF 1 α; the stable breakdown product of PGI 2 ; Nies, 1986; Liu et al. 1997) , and 11-dehydro-thromboxane B 2 (11-dehydro-TxB 2 ; the stable plasma breakdown product of TxA 2 ; Catella et al. 1986 ) in response to challenge with arachidonic acid (10 −6 M) was assessed using pooled conduit veins (e.g. femoral, saphenous) from LZR and OZR. Pooled vessels from each animal were incubated in microcentrifuge tubes in 1 ml of PSS for 30 min under control conditions (21% O 2 with the arachidonic acid challenge). After this time, the superfusate was removed, stored in a new microcentrifuge tube and frozen in liquid N 2 , while a new aliquot of PSS with arachidonic acid was added to the vessels for the subsequent 30 min. After the second 30 min period, this PSS was transferred to a fresh tube, frozen in liquid N 2 and stored at −80°C. Metabolite release by the vessels was determined using commercially available EIA kits for 6-keto-PGF 1α and 11-dehydro-TxB 2 (Cayman Chemical Co., Ann Arbor, MI, USA). Data are means ± SD. * P < 0.05 versus LZR. MAP, mean arterial pressure; MCP-1, monocyte chemoattractant protein 1; TNF-α, tumour necrosis factor α.
Data and statistical analyses
Blood flow in venular segments within in situ cremaster muscle of LZR and OZR was calculated as:
where Q represents venular perfusion (nl s −1 ), V represents the measured red cell velocity from the optical Doppler velocimeter (mm s −1 ; with V/1.6 representing an estimated average velocity assuming a parabolic flow profile; Baker and Wayland, 1974) , and r represents venular radius (μm; Davis, 1987) .
All data are presented as the mean ± SD. Statistically significant differences in measured and calculated parameters between LZR and OZR in the present study were determined using repeated measures analysis of variance (RM-ANOVA), where agonist concentration or muscle stimulation frequency were used as the repeated measures. Statistically significant differences in arachidonic acid metabolite production, leukocyte adhesion/rolling and measures of microvessel density between LZR and OZR were assessed using standard ANOVA or Student's t test, as appropriate. Student-Newman-Keuls post hoc test was used when appropriate and P < 0.05 was taken to reflect statistical significance. 
Results
At ß17 weeks, OZR exhibited all aspects of the metabolic syndrome, being obese as compared to age-matched LZR, with impaired glycaemic control, with dyslipidaemia in both cholesterol and triglyceride levels and a moderate level of hypertension (Table 2 ). In addition, OZR exhibited both a chronic level of oxidant stress within the vasculature as well as a chronic state of inflammation. Within the in situ cremaster muscle, venular diameters under untreated conditions demonstrated a modest reduction in diameter in OZR as compared to LZR, and there was no difference in venular diameter under passive conditions. When taken together, however, calculated active tone of in situ venules for OZR in the post-capillary level, but not in the collecting venules, was elevated as compared to that for LZR. Fig. 1E ). In response to increasing concentrations of acetylcholine, dilator responses of both distal and proximal venules of OZR were attenuated as compared to responses in LZR. Venules from OZR and LZR all demonstrated a robust constriction in response to increasing concentrations of endothelin, angiotensin II and clonidine (Fig. 1B-D) , although there were no demonstrable differences in these responses between strains. However, venular constrictor responses to increasing concentrations of the α 1 -adrenoreceptor agonist phenylephrine were significantly increased in OZR over the mid-range of the agonist challenge (Fig. 1E) .
Data describing the reactivity of collecting venules within the in situ cremaster muscle of LZR and OZR are presented in Fig. 2 . As with the smaller venules, dilator responses of larger collecting venules to acetylcholine were attenuated in OZR as compared to responses in LZR ( Fig. 2A) , while responses to increasing concentrations of endothelin (Fig. 2B ) and angiotensin II (Fig. 2C) were comparable. However, while venular constrictor responses to phenylephrine were enhanced in OZR as compared to LZR (Fig. 2D ), responses to clonidine (Fig. 2E) were also increased versus those in LZR. Figure 3 presents the mechanistic contributors to the venular dilatation to acetylcholine in post-capillary venules of LZR ( Fig. 3A and C) and OZR ( Fig. 3B  and D) . In LZR, dilator responses of venules to increasing concentrations of acetylcholine were largely nitric oxide dependent, as treatment with L-NAME significantly attenuated responses (Fig. 3A) . While there was a contribution from cyclooxygenase products to this response, it was less substantial than that for nitric oxide. In OZR, the attenuated venular dilatation to acetylcholine was abolished following treatment of the cremaster muscle with L-NAME, but only minimally impacted as a result of treatment with indomethacin. However, incubation of the tissue with TEMPOL resulted in a more robust dilatation to increasing concentrations of acetylcholine (Fig. 3B) . If the cremaster muscle of LZR or OZR was incubated with TEMPOL prior to challenge with increasing concentrations of acetylcholine, these relationships were not fundamentally altered in venules of LZR (Fig. 3C) . However, the improvement in the acetylcholine-induced venular dilatation in OZR was abolished by L-NAME, unaffected by indomethacin, and mildly improved by blockade of PGH 2 /TxA 2 receptors with SQ-29548 (Fig. 3D) .
The relationships between acetylcholine-induced dilatation (with or without pre-treatment with TEMPOL) and its basic mechanistic contributors were consistent in the larger collecting venules within in situ cremaster muscle of LZR and OZR with some exceptions (Fig. 4A-D) . In post-capillary venules from LZR and OZR rats and in collecting venules from OZR, indomethacin did not have a demonstrable impact on dilator responses to acetylcholine, but significantly attenuated collecting venular dilatation in LZR. Further, the indomethacin-sensitive component of the collecting C and D, respectively) , where the cremaster muscle was subsequently treated with L-NAME, indomethacin (INDO) or SQ-29548 to assess the contributions of nitric oxide, cyclooxygenase products or PGH 2 /TxA 2 to reactivity. Data are presented as the mean ± SD change in venular inner diameter, expressed as a percentage of the initial resting state (ß25 µm). * P < 0.05 versus responses from LZR at that agonist concentration. For A and B, results represent n = 6 observations from 12 animals in LZR; n = 6 observations from 12 animals in OZR. For C and D, results represent n = 6 observations from 12 animals in LZR; n = 6 observations from 12 animals in OZR. All statistical analyses were done on the number of observations within the group, not the number of animals within the group. See text and Table 1 for details.
J Physiol 595.15 venular dilatation to acetylcholine was absent in OZR and in LZR and OZR pre-treated with TEMPOL. Using prazosin (α 1 -adrenergic receptor blocker) and yohimbine (α 2 -adrenergic receptor blocker), alone and in combination, the constrictor responses of post-capillary and collecting venules within cremaster muscle of LZR and OZR in response to increasing concentrations of noradrenaline were demonstrated to be almost entirely α 1 -receptor dependent in post-capillary venules and predominantly α 1 -receptor dependent (with a smaller contribution from α 2 -adrenergic receptors) in collecting venules in both strains (data not shown). Data describing the interaction of altered endothelial function and the venular constriction to increasing concentration of noradrenaline are summarized in Fig. 5 . In the immediate post-capillary venules, treatment of the cremaster muscle with L-NAME increased constrictor responses to noradrenaline in LZR (Fig. 5A) , but was without effect in OZR (Fig. 5B ). While treatment with indomethacin was largely without effect in either strain, treatment of the muscle with TEMPOL had only a minor effect on venular responses in LZR, but attenuated the constrictor response in OZR venules. Following pre-treatment of the cremaster muscle with TEMPOL in LZR, responses to increasing concentrations of noradrenaline and the impact of L-NAME, indomethacin and SQ-29548 were similar to that determined under untreated conditions (Fig. 5C ). In contrast, pre-treatment of the cremaster 
. Mechanisms of altered collecting venular dilation to acetylcholine in LZR and OZR under untreated conditions and following pre-treatment with TEMPOL
A and B, the dilator reactivity of collecting venules within in situ cremaster muscle of LZR and OZR in response to increasing concentrations of acetylcholine (A and B, respectively). Data are presented for venular reactivity under untreated control conditions, and following pre-treatment of the cremaster muscle with L-NAME, indomethacin (INDO) or TEMPOL. C and D, data describing the reactivity of collecting venules following pre-treatment with TEMPOL to normalize responses in LZR and OZR (C and D, respectively), where the cremaster muscle was subsequently treated with L-NAME, indomethacin (INDO) or SQ-29548 to assess the contributions of nitric oxide, cyclooxygenase products or PGH 2 /TxA 2 to reactivity. Data are presented as the mean ± SD change in venular inner diameter, expressed as a percentage of the initial resting state (ß70 µm). * P < 0.05 versus responses from LZR at that agonist concentration. For A and B, results represent n = 6 observations from 12 animals in LZR; n = 6 observations from 12 animals in OZR. For C and D, results represent n = 6 observations from 12 animals in LZR; n = 6 observations from 12 animals in OZR. All statistical analyses were done on the number of observations within the group, not the number of animals within the group. See text and Table 1 for details.
muscle of OZR with TEMPOL (moderating the severity of the noradrenaline-induced constriction) shifted venular reactivity such that constrictor responses were increased following treatment with L-NAME, were unaffected by indomethacin, but were reduced following additional treatment with SQ-29548 (Fig. 5D ). Comparable to the responses to acetylcholine challenge, these relationships between noradrenaline-induced venular constriction (with or without pre-treatment with TEMPOL) and its basic contributors were similar in the collecting venules within in situ cremaster muscle of LZR and OZR ( Fig. 6A-D) . In response to field stimulation of the in situ cremaster muscle of LZR and OZR at increasing metabolic demand, the dilator and perfusion responses of post-capillary and collecting venules are summarized in Fig. 7 . In response to increasing metabolic demand, the dilator responses of post-capillary (Fig. 7A) and collecting (Fig. 7B) cremaster muscle venules was attenuated at the low (0.5 Hz) and moderate (1.0 Hz) contraction frequencies, but was similar at the high (2.0 Hz) contraction frequency. Perfusion responses followed a similar pattern, exhibiting a restrained hyperaemic response at the lower two contraction frequencies in both post-capillary (Fig. 7C) and colleting (Fig. 7D) venules that was not present at the high contraction frequency.
Pre-treatment of the cremaster muscle with TEMPOL moderated this difference in metabolism-induced venular dilatation in the post-capillary venules of OZR, but had no significant effect on the dilator responses to muscle contraction in the larger collecting venules ( Fig. 8A  and B) . A similar impact was determined on blood flow responses, where hyperaemia was improved in both venular diameter ranges, although responses in the larger venules failed to achieve statistical significance ( Fig. 8C  and D) . In contrast, pre-treatment of the cremaster muscle with phentolamine (α 1 /α 2 -adrenoreceptor blocker) had minimal impact on contraction-induced dilatation or perfusion in post-capillary venules ( Fig. 8A and C) , although both the dilator and hyperaemic responses were improved in the larger collecting venules (Fig. 8B and D) . The venous production of PGI 2 and TxA 2 in response to challenge with arachidonic acid is summarized in Fig. 9 . Venous PGI 2 production, estimated from the levels of 6-keto-PGF 1 α, was reduced in OZR as compared to levels in LZR under control conditions (Fig. 9A) . Pre-treatment of the pooled veins with TEMPOL had no effect on responses in LZR, but resulted in an increase in the production of PGI 2 in OZR. In contrast, venous production of TxA 2 , estimated from the levels of 11-dehydro-TxB 2 , was elevated in OZR vs. LZR under control conditions (Fig. 9B) , but was reduced toward levels determine in LZR following pre-treatment of veins with TEMPOL. Venous production of either PGI 2 or TxA 2 was abolished following treatment of the vessels with indomethacin.
Data describing the adhesion and rolling of leukocytes in the post-capillary venules of the in situ extensor A and B, the constrictor reactivity of collecting venules within in situ cremaster muscle of LZR and OZR in response to increasing concentrations of noradrenaline (A and B, respectively). Data are presented for venular reactivity under untreated control conditions, and following pre-treatment of the cremaster muscle with L-NAME, indomethacin (INDO) or TEMPOL. C and D, data describing the reactivity of collecting venules following pre-treatment with TEMPOL in LZR and OZR (C and D, respectively), where the cremaster muscle was subsequently treated with L-NAME, indomethacin (INDO) or SQ-29548 to assess the contributions of nitric oxide, cyclooxygenase products or PGH 2 /TxA 2 to reactivity. Data are presented as the mean (±SD) change in venular inner diameter, expressed as a percentage of the initial resting state (ß70 µm). * P < 0.05 versus responses from LZR at that agonist concentration. For A and B, results represent n = 6 observations from 12 animals in LZR; n = 6 observations from 12 animals in OZR. For C and D, results represent n = 6 observations from 12 animals in LZR; n = 6 observations from 12 animals in OZR. All statistical analyses were done on the number of observations within the group, not the number of animals within the group. See text and Table 1 for details.
digitorum longus muscle of LZR and OZR are summarized in Fig. 10 . For both adhesion of leukocytes and rolling of adherent cells, responses were increased in the networks of OZR as compared to that for LZR. Figure 11 presents data describing microvessel and post-capillary venular density within skeletal muscle of OZR and LZR. In both cases, microvascular and post-capillary venular density were significantly reduced in OZR as compared to levels in age-matched LZR.
Discussion
To date, studies elucidating the impact of the metabolic syndrome on vascular regulation have focused on arterial/arteriolar control. However, the arterial/arteriolar dysregulation observed in the metabolic syndrome is (at least partially) a result of a pro-oxidant, pro-inflammatory and pro-thrombotic environment, conditions which are known to also impact the venular/venous side of the circulation. In an effort to provide a foundation from which more targeted investigation can be directed, the present study investigated the impact of the metabolic syndrome on skeletal muscle venular function at two levels (post-capillary and collecting venules). Further, it was recently suggested that the pro-inflammatory and pro-oxidant conditions observed in post-capillary venules may be the initiating site for microvascular rarefaction that is commonly associated with chronic metabolic disease (Gilbert, 2013; Frisbee et al. 2014; Clough, 2015) and that fluid handling across the microcirculation may be altered by chronic impairments to glycaemic control (Huxley & Scallan, 2011; Scallan et al. 2015) .
In the present study, impaired acetylcholine-induced venular dilatation in OZR appeared to be a result of elevated oxidative stress on venular nitric oxide bioavailability, as treatment of the cremaster muscle with the antioxidant TEMPOL partially restored venular function to that determined in LZR. While this is consistent with data determined in multiple organs (Tune et al. 2017) and across arterial/arteriolar levels (Goodwill & Frisbee, 2012) , these data are critical for our understanding of both capillary handling of erythrocytes and fluid exchange across the microcirculation. Interestingly, there appears to be a role for an increased arachidonic acid-induced production of TxA 2 in the loss of normal endothelium-dependent dilator reactivity, which is likely to be associated with the chronic pro-inflammatory condition observed in OZR. While this increase in TxA 2 can have multiple effects, including impacting leukocyte adhesion (Morris et al. 2009; Singer et al. 2009; Tole et al. 2010; Totani et al. 2012) and venular reactivity and responses, this also may represent a mechanism for modifying fluid filtration/absorption across the capillary networks under settings of chronic metabolic disease (Huxley and Scallan, 2011; Scallan et al. 2015) as well as contributing to the genesis of the microvessel rarefaction discussed above . Similar to arteries and arterioles, the sympathetic nervous system is a major regulator of venous and venular tone, with sympathetic nerve fibres directly innervating α 1 -and α 2 -adrenoreceptors on vascular smooth muscle cells (Mellander & Lewis, 1963; van Brummelen et al. 1986; Tabrizchi and Pang, 1992) . However, in contrast to arterioles, increased sympathetic nerve activity to small veins and venules results in a reduction in vascular compliance, thus altering venous volume (capacitance) with comparatively less impact on systemic resistance (Rothe, 1983) Table 1 for details.
addition to α 1 -and α 2 -adrenoreceptor-mediated control, sympathetic activity can modify venous or venular tone through NPY Y1 receptor activation (Luu et al. 1992; Pongor et al. 2010) .
The results from the present study suggest that venular reactivity to adrenergic stimuli was elevated in OZR vs. LZR, with this effect being predominantly mediated via the α 1 -adrenoreceptor, but with an apparent role for the α 2 -adrenoreceptor as well in the larger collecting venules. While there appeared to be a contribution to this effect mediated via the impaired endothelial function, it was not clear that these contributions, whether mediated via a loss of nitric oxide bioavailability or an increase in venular levels of TxA 2 , were significant contributors to the altered tone regulation. However, it was clear this represented an alteration to adrenergic signalling itself, and not a broad-spectrum shift in venular constrictor reactivity at either the post-capillary or collecting venular level of the microcirculation.
The alterations to venular reactivity between LZR and OZR take on additional significance when evaluated in response to metabolic challenge. Increasing metabolic demand, instigated via electrical field stimulation of the cremaster muscle at increasing frequency (Saito et al. 1994; McKay et al. 1998) , resulted in a functional dilator and hyperaemic response in OZR that was restrained in comparison to that determined in LZR, with the exception of the highest frequency of stimulation (3 Hz; where responses between LZR and OZR venules were comparable).
Previous work by Hester's group has implicated the venular release of prostacyclin (PGI 2 ), as a contributing mechanism to the dilatation of the adjacent arterioles that perfuse the capillary network under conditions of elevated metabolic demand in skeletal muscle (Saito et al. 1994; McKay et al. 1998; Hester & Hammer, 2002) . Further, it has also been established that, under conditions of high oxidant stress and inflammation, the production of PGI 2 can be shifted to TxA 2 (Zou, 2007) , and that there is an increased arterial (Xiang et al. 2006; Goodwill et al. 2008; Butcher et al. 2013 ) and venous (above) production of TxA 2 in OZR manifesting the metabolic syndrome. Speculatively, it may be that the negative impact of vascular production of TxA 2 on muscle perfusion that has been demonstrated previously may partially be of venular origin, impacting not only its own reactivity, but also the calibre of adjacent resistance arterioles leading into the microcirculation and contributing to the loss in overall system flexibility and adaptive potential to imposed challenges (Hester & Hammer, 2002; Frisbee et al. 2016) . This speculation requires further investigation.
As has been well established, the venular circulation is a low pressure 'collecting network' for the output of the high pressure 'distribution network' of arteriolar perfusion through the capillaries. While the increased adrenergic reactivity and impaired endothelial function can serve to increase venular tone, the extent to which this shift in function acts to increase perfusion resistance across the microcirculation is unclear at this time and will require additional investigation. However, given the observation of an increased leukocyte adhesion to the venular endothelium, this physical blockade has been previously demonstrated to increase perfusion resistance within those regions (Lipowsky et al. 1988 . Venous production of 6-keto-PGF 1 α (from PGI 2 ; A) and 11-dehydro-TxB 2 (from TxA 2 ; B) following challenge with arachidonic acid in pooled vessels from LZR and OZR Data (mean ± SD) are presented under control conditions for each strain, and following pre-treatment of the pooled vessels with either TEMPOL or indomethacin (INDO). * P < 0.05 versus responses from LZR within the treatment group. Results represent n = 6 observations from 6 animals in LZR; n = 6 observations from 6 animals in OZR. All tissues for these ex vivo experiments were taken from animals within experiment groups 1 and 2. See text for details.
J Physiol 595.15 Skalak, 1993; Harris et al. 1994) through the establishment of regions of 'low radius' that are no longer functionally able to effectively regulate diameter. From the perspective of mass transport and exchange, the extent to which an increase in venular tone is sufficient to elevate resistance downstream from the capillaries is unclear. erythrocyte distribution heterogeneity and lowered microvascular haematocrit previously reported in OZR ). An obvious implication for the increase in venular resistance would also be an increase in the intravascular pressure within the venular environment, leading to an increased net fluid filtration into the tissue across the microcirculation. A recent study by Scallan et al. (2015) may provide insight into this outcome as the loss of nitric oxide bioavailability in the lymphatic vessels of diabetic mice (where vascular nitric oxide levels have also been established to be impaired) results in a release on the inhibition of phosphodiesterase 3 (PDE3), compromising lymphatic integrity and increasing tissue oedema. It will be intriguing to determine if this fascinating observation on fluid handling across the microcirculation in diabetes represents multiple contributing pathways involving impaired venular function as well.
In summary, with the development of the metabolic syndrome, venular function within the skeletal muscle of OZR is impaired at both the post-capillary and collecting venular segments. Along with an impaired endothelium-dependent dilatation and a modest increase in adrenergic constriction, a significant elevation in TxA 2 production may act to impair functional dilator and hyperaemic responses at the venular level, and may contribute to the impaired function at the adjacent arteriolar level as well (Hester & Hammer, 2002) . The implications of this shift in skeletal muscle venular function with the development of the metabolic syndrome for issues such as aggregate microvascular perfusion resistance, mass transport and exchange within with capillary networks, and fluid handling across the microcirculation are compelling avenues for future interrogation.
